My Next Health Inc. is pleased to announce it has secured a $150 million equity capital commitment through a share subscription facility entered into with GEM Global Yield LLC SCS a Luxembourg-based private alternative investment group.
Under the agreement, GEM has agreed to purchase, for a period of 36 months after a public listing of MNH’s common stock, up to $150 million in shares from time to time upon MNH’s drawdown request. The Company will have no minimum drawdown obligation and will be authorized to utilize the facility on an as-needed basis during the term of the agreement. Subject to certain exceptions, the subscription price for shares to be purchased by GEM under the facility will be based on a 10% discount to the market price of MNH’s shares at such time. In connection with the share subscription facility, on public listing, MNH will issue warrants to GEM to purchase, for a period of three years after a public listing of MNH’s common stock, up to 7.8% of the total equity interests of MNH as of such public listing date at an exercise price equal to the public offering price at the time of MNH’s public listing and subject to a $500M valuation cap. Notwithstanding the foregoing transaction or anything to the contrary herein, there can be no assurance that MNH will achieve a public listing in the near future, or at all.
“Securing this capital commitment from the GEM Group propels us forward on the path to improving human health by accelerating the world’s transition to precision medicine,” Chief Executive Officer of MNH, Dr. Richard Heinzl, was quoted. “Working with a strong capital partner like the GEM Group is a valuable support to our business strategy as we look forward to achieving significant corporate objectives in the coming months.”
About The GEM Group
Global Emerging Markets (“GEM“) is a $3.4 billion alternative investment group with offices in Paris, New York, and Nassau (Bahamas). GEM manages a diverse set of investment vehicles focused on emerging markets and has completed over 480 transactions in 70 countries. Each investment vehicle has a different degree of operational control, risk-adjusted return, and liquidity profile. The family of funds and investment vehicles provide GEM and its partners with exposure to: Small-Mid Cap Management Buyouts, Private Investments in Public Equities (PIPEs) and select venture investments. http://www.gemny.com.
About MNH
My Next Health Inc. (“MNH” or the “Company“) is incorporated pursuant to the General Corporation Law of the State of Delaware. The Company’s vision is to improve human health and accelerate the world’s transition to precision medicine through ground-breaking clinical trials and digital therapeutic platforms. This will be done using unique functional genomics insights derived from thousands of case studies into the associations between genes, metabolic pathways and health outcomes.
